精優藥業(00858.HK)擬折價17.8%配售1.6億股 總籌1552萬港元拓展大健康業務
格隆匯8月15日丨精優藥業(00858.HK)發佈公告，2025年8月14日，公司與認購方I(即曾廣釗)訂立認購協議I，據此，認購方I已有條件同意認購，而公司已有條件同意按認購價(相等於每股認購股份I 0.097港元)配發及發行合共3000萬股認購股份I。認購股份I相當於公司現有已發行股本約1.26%；及經配發及發行認購股份I擴大的已發行股本約1.24%。認購價每股認購股份I 0.097港元較8月14日(即認購協議I的日期)在聯交所所報收市價每股0.118港元折讓約17.80%。
2025年8月14日，公司與認購方II(即張曉佳)訂立認購協議II，據此，認購方II已有條件同意認購，而公司已有條件同意按認購價II(相等於每股認購股份II 0.097港元)配發及發行合共2000萬股認購股份II。認購股份II相當於公司現有已發行股本約0.84%；及經配發及發行認購股份II擴大已發行股本約0.83%。
同日，公司與認購方III(即Fudan Health International Ltd.)訂立認購協議III，據此，認購方III已有條件同意認購，而公司已有條件同意按認購價III(相等於每股認購股份III 0.097港元)配發及發行合共1.1億股認購股份III。認購股份III相當於公司現有已發行股本約4.6%；及經配發及發行認購股份III擴大的已發行股本約4.4%。認購股份I、認購股份II及認購股份III將根據一般授權配發及發行，該授權自授出以來未曾動用。
假設所有認購股份I成功發行，發行認購股份I的所得款項總額及所得款項淨額將分別約爲291萬港元及289萬港元。假設所有認購股份II成功發行，發行認購股份II的所得款項總額及所得款項淨額將分別約爲194萬港元及193萬港元。假設所有認購股份III成功發行，發行認購股份III的所得款項總額及所得款項淨額將分別約爲1067萬港元及1060萬港元。公司擬將認購事項的所得款項淨額用於集團在中國的保健產品、設備和技術貿易、製造、銷售和分銷業務的潛在新業務發展，並將與保健領域相關的業務機會擴展至海外市場，同時集團將繼續通過分配其現有內部產生的現金資源來維持和發展其現有的醫藥業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
